STOCK TITAN

SOPHiA GENETICS (SOPH) CPO awarded options, RSUs and corrects holdings

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4/A

Rhea-AI Filing Summary

SOPHiA GENETICS SA Chief People Officer Manuela Valente received new equity awards and corrected her reported share holdings. She was granted an option for 104,790 ordinary shares at an exercise price of $5.04 per share, expiring on April 2, 2036. She also received 71,869 restricted stock units, each representing one ordinary share, with 25% vesting on April 2, 2027 and the remaining 75% vesting in equal quarterly installments through April 2, 2030, subject to continued service. Following these awards and a correction to a prior report, her directly held ordinary shares are reported as 224,248.

Positive

  • None.

Negative

  • None.
Insider Valente Manuela
Role Chief People Officer
Type Security Shares Price Value
Grant/Award Share Option (Right to Buy) 104,790 $0.00 --
Grant/Award Ordinary Shares 71,869 $0.00 --
Holdings After Transaction: Share Option (Right to Buy) — 104,790 shares (Direct); Ordinary Shares — 224,248 shares (Direct)
Footnotes (1)
  1. Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030. This Form 4/A amends the Form 4 filed on April 3, 2026 to correct the amount reported in Column 5 (Amount of Securities Beneficially Owned Following Reported Transaction), which was previously reported as 71,869 ordinary shares due to an inadvertent error. The correct amount is 224,248 ordinary shares. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.
Stock option grant size 104,790 shares Share option granted on April 2, 2026
Option exercise price $5.04 per share Exercise price for 104,790-share option
Option expiration April 2, 2036 Expiration date of share option
RSU grant size 71,869 RSUs RSU grant under 2021 Equity Incentive Plan
Shares beneficially owned 224,248 ordinary shares Corrected amount following reported transactions
Initial RSU vesting 25% on April 2, 2027 First vesting tranche for RSU grant
Remaining RSU vesting period Through April 2, 2030 Remaining RSUs vest quarterly to 2030
restricted stock unit ("RSU") financial
"Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan."
2021 Equity Incentive Plan financial
"grant made under the Issuer's 2021 Equity Incentive Plan."
vest financial
"25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
beneficially owned financial
"correct the amount reported in Column 5 (Amount of Securities Beneficially Owned Following Reported Transaction)"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
share option vests and becomes exercisable financial
"The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027"
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Valente Manuela

(Last)(First)(Middle)
C/O SOPHIA GENETICS SA
LA PIECE 12

(Street)
ROLLE1180

(City)(State)(Zip)

SWITZERLAND

(Country)
2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief People Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/02/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)
04/03/2026
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Ordinary Shares04/02/2026A71,869(1)A$0224,248(2)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Share Option (Right to Buy)$5.0404/02/2026A104,790 (3)04/02/2036Ordinary Shares104,790$0104,790D
Explanation of Responses:
1. Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030.
2. This Form 4/A amends the Form 4 filed on April 3, 2026 to correct the amount reported in Column 5 (Amount of Securities Beneficially Owned Following Reported Transaction), which was previously reported as 71,869 ordinary shares due to an inadvertent error. The correct amount is 224,248 ordinary shares.
3. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.
Remarks:
/s/ Elimara Brunetto as Attorney-in-fact for Manuela Valente04/08/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did SOPH Chief People Officer Manuela Valente receive?

Manuela Valente received a share option for 104,790 ordinary shares at a $5.04 exercise price and 71,869 restricted stock units. These compensation awards increase her potential ownership in SOPHiA GENETICS SA if vesting and, for options, future exercises occur.

How do the new RSUs for SOPH’s Manuela Valente vest over time?

The 71,869 RSUs vest 25% on April 2, 2027, with the remaining 75% vesting in equal quarterly installments through April 2, 2030. Vesting is conditioned on her continued service with SOPHiA GENETICS SA during this period.

What are the terms of Manuela Valente’s new SOPH stock option grant?

The grant covers 104,790 ordinary shares at a $5.04 exercise price and expires April 2, 2036. Twenty-five percent vests on April 2, 2027, and the rest vests in equal monthly installments through April 2, 2030, subject to continued service.

How many SOPHiA GENETICS SA ordinary shares does Manuela Valente now beneficially own?

After correcting a prior reporting error, her beneficially owned ordinary shares are reported as 224,248. A previous Form 4 had mistakenly shown 71,869 shares in that column, which this amended filing states was incorrect.

Why was this Form 4/A amendment filed for SOPH’s Manuela Valente?

The amendment corrects the amount of securities beneficially owned after the reported transaction. A prior Form 4 had inadvertently reported 71,869 ordinary shares; this filing states the correct total is 224,248 ordinary shares following the transaction.

Are Manuela Valente’s new SOPH awards open-market purchases or compensation grants?

Both transactions are coded as grants or awards, not open-market purchases. The option and RSU awards were made under SOPHiA GENETICS SA’s 2021 Equity Incentive Plan as part of her compensation, with no cash purchase price reported per share.